Image
Online Portal, EMR Integrations, and Data Transfers

Online Portal, EMR Integrations, and Data Transfers

Foundation Medicine's online portal, EMR integrations, and data transfers provide you and your care team with the resources needed to incorporate comprehensive genomic profiling into your workflow.

Services for Workflow Integration

We aim to make integrating comprehensive genomic profiling (CGP) into your practice as seamless as possible. That’s why we offer multiple modalities to order Foundation Medicine tests and receive reports.

Foundation Medicine's Online Portal is designed to improve you and your care teams' workflow. For pathology labs, we provide a Pathology Portal to access reports for specimens sent by your lab.

For health systems and cancer care networks, we support your care team by facilitating EMR integrations and data transfers to enhance your clinical workflow efficiency and create easy access to patients' clinical and genomic data, all in one place. 

Learn More Below

EMR Integration & Data Transfer

Image

Never leave your EMR. Foundation Medicine integrates into all EMRs to enhance your clinical workflow efficiency and create easy access to patients’ clinical and genomic data all in one place.

By partnering with leading EMR vendors (Epic, OncoEMR, Oracle/Cerner, MEDITECH and others), Foundation Medicine can support your health system or care network to implement seamless integration for test ordering and results (PDF and discrete data) directly into your patient chart. 

You can find our portfolio of tests integrated into your EMRs including: 

Comprehensive Portfolio: IHC tests: 
FoundationOne®CDxDako PD-L1 22C3 pharmDx
FoundationOne®RNADako PD-L1 28-8 pharmDx
FoundationOne®Liquid CDxVentana PD-L1 SP142
FoundationOne®HemeVentana PD-L1 SP263
 Ventana HER2 (4B5) Antibody 
 Ventana FOLR1 (FOLR1-2.1) RxDx

Foundation Medicine fully supports the transfer of genomic data in multiple formats including VCF, JSON, XML, BAM etc. for research purposes. 

For questions regarding our EMR integrations and or data transfers, please contact our EMR Integration Specialist or reach out to our team at Commercial.Programs @FoundationMedicine.com or +1 (888) 988-3639.

Online Ordering & Digital Reporting Experience

Foundation Medicine’s Digital Experience

Image
OORI_02_01_onlineordering.png

Foundation Medicine’s online portal for ordering guides you and your care team throughout the ordering experience from test selection process, to auto-filled fields, and ease of uploading supplemental information (e.g. insurance, pathology report, Advanced Beneficiary Notice (ABN), or Letter of Medical Necessity (LMN)).  

Our guided portal ordering process prevents order submissions with missing information, reducing entry errors and order delays. 

Image
OORI_04_03_mobileapp.png

On the go? Be sure to plan follow-ups accordingly with the ability to check status for your patient’s report with estimated time of arrival, receive notifications when orders are placed on hold, view and download patient reports, and submit inquiries about your patient’s results, all from your smart phone through the Foundation Medicine mobile app.

Additional Notes

Epic® is a registered trademark of Epic Systems Corporation. OncoEMR® is a registered trademark of Flatiron Health.

FoundationOne®CDx is a qualitative next-generation sequencing based in vitro diagnostic test for advanced cancer patients with solid tumors and is for prescription use only. The test analyzes 324 genes as well as genomic signatures including microsatellite instability (MSI ) and tumor mutational burden (TMB ) and is a companion diagnostic to identify patients who may benefit from treatment with specific therapies in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy. For the complete label, including companion diagnostic indications and important risk information, please visit www.F1CDxLabel.com

FoundationOne®RNA is a laboratory developed test that was developed and its performance characteristics determined by Foundation Medicine. FoundationOne RNA has not been cleared or approved by the U.S. Food and Drug Administration. FoundationOne RNA is a test for solid tumors which utilizes RNA sequencing to interrogate 318 cancer-related genes to capture gene fusions and rearrangements. A negative result does not rule out the presence of an alteration. Genomic findings are not prescriptive or conclusive for labeled use of any specific therapeutic product.

FoundationOne®Liquid CDx is for prescription use only and is a qualitative next-generation sequencing based in vitro diagnostic test for advanced cancer patients with solid tumors. The test analyzes 324 genes utilizing circulating cell-free DNA and is FDA-approved to report short variants in 311 genes and as a companion diagnostic to identify patients who may benefit from treatment with specific therapies (listed in Table 1 of the Intended Use) in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Patients being considered for eligibility for therapy based on detection of NTRK1/2/3 and ROS1 fusions should only be tested if tissue is unavailable. Patients who are negative for other companion diagnostic mutations should be reflexed to tumor tissue testing and mutation status confirmed using an FDA-approved tumor tissue test, if feasible. For the complete label, including companion diagnostic indications and complete risk information, please visit www.F1LCDxLabel.com

FoundationOne®Heme is a laboratory developed test that combines DNA sequencing of 406 genes and RNA sequencing of 265 genes for patients with hematologic malignancies, sarcomas or solid tumors where RNA sequencing is desired. The test can be used by physicians to identify potential targeted therapy options, detect alterations in prognostic genes, and sub-classify sarcoma diagnoses. For more information on FoundationOne Heme, please see its Technical Specifications at www.foundationmedicine.com/heme

Questions? We’re Here to Help

Please contact our client services team by phone at +1(888) 988-3639 or by email at the link below.

Email Us